Effective or announced 29 September 2026Impact for foreign investors: medium
What changed
The US widened its 100% tariff on specified patented medicines from 29 September 2026 to cover more companies. Generic medicines and their ingredients are outside the tariff. India is one of 20 eligible jurisdictions whose qualifying speciality medicines may get zero duty.
Who it affects
Pharma groups manufacturing in India for the US market, and investors in Indian export capacity.
What to do
Classify your US-bound portfolio between generics, speciality and patented products and confirm eligibility for zero duty.